The Multifaceted Roles of Tau: From Microtubule Stabilizer to Neurodegenerative Driver and Therapeutic Target

Abstract

Tau protein, a microtubule-associated protein (MAPT), is intrinsically linked to the pathogenesis of numerous neurodegenerative diseases, collectively termed tauopathies. While its physiological role in stabilizing microtubules and regulating axonal transport is well-established, aberrant modifications, particularly hyperphosphorylation, drive its aggregation into neurofibrillary tangles (NFTs), a hallmark of Alzheimer’s disease (AD) and other tauopathies. This report provides a comprehensive overview of tau, encompassing its structural and functional properties, the mechanisms underlying its pathological transformation, the genetic and environmental factors influencing tau pathology, the diverse isoforms of tau and their disease relevance, and the latest advancements in therapeutic strategies targeting tau. Furthermore, we examine diagnostic modalities for in vivo tau imaging and the correlation between tau burden and cognitive decline. Beyond its well-defined role in AD, we explore the emerging evidence implicating tau in other neurological disorders and its potential involvement in broader cellular processes. This review aims to provide an expert-level perspective on the multifaceted roles of tau, highlighting both its critical physiological functions and its detrimental contribution to neurodegeneration, while also emphasizing the challenges and opportunities in developing effective tau-targeted therapies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Microtubule-associated protein tau (MAPT), commonly referred to as tau, is a protein primarily expressed in neurons, where it plays a crucial role in stabilizing microtubules, the dynamic scaffolding of the cell [1]. Microtubules are essential for axonal transport, neuronal morphology, and synaptic function, all of which are vital for proper neuronal signaling and overall brain health. Under physiological conditions, tau binds to microtubules, promoting their assembly and stability. However, in a variety of neurodegenerative diseases, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), tau undergoes aberrant post-translational modifications, most notably hyperphosphorylation [2]. This hyperphosphorylation disrupts tau’s ability to bind to microtubules, causing it to detach and aggregate into paired helical filaments (PHFs), the major structural component of NFTs [3].

The formation of NFTs is a defining pathological feature of these tauopathies and is strongly correlated with neuronal dysfunction and cognitive decline [4]. The mechanism by which tau aggregation leads to neuronal dysfunction is complex and multifactorial. The loss of functional tau from microtubules impairs axonal transport, disrupting the delivery of essential proteins and organelles to synapses. Furthermore, tau aggregates are believed to be toxic, interfering with cellular processes and triggering inflammatory responses. The spread of tau pathology throughout the brain follows a characteristic pattern in AD, as described by Braak staging [5], suggesting a prion-like propagation mechanism [6].

While the role of tau in neurodegenerative diseases is well-established, recent research has revealed more nuanced aspects of its function and dysfunction. For instance, tau has been implicated in DNA protection, stress granule formation, and regulation of neuronal excitability [7, 8]. Understanding these broader functions is crucial for developing targeted therapies that can selectively inhibit the pathological effects of tau without disrupting its essential physiological roles. The complexity of tau pathology and its diverse roles in the cell necessitates a comprehensive understanding of its structure, function, regulation, and involvement in both health and disease.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Structure and Function of Tau

2.1. Tau Isoforms and Domains

The MAPT gene encodes six isoforms of tau in the human brain, generated through alternative splicing of exons 2, 3, and 10 [9]. These isoforms vary in the number of N-terminal inserts (0N, 1N, or 2N) and the presence or absence of a second microtubule-binding repeat (3R or 4R). All isoforms contain a C-terminal region involved in microtubule binding and aggregation. The relative abundance of 3R and 4R tau isoforms is tightly regulated in healthy brains, with a roughly equal ratio. However, this balance is often disrupted in tauopathies, leading to a preponderance of either 3R or 4R tau, depending on the specific disease [10]. For example, Pick’s disease (PiD) is characterized by an accumulation of 3R tau, while PSP and CBD show an accumulation of 4R tau. AD features a mixed population of both 3R and 4R tau isoforms.

The primary structure of tau can be divided into several functional domains. The N-terminal region contains acidic proline-rich domains that interact with SH3 domains of signaling proteins, suggesting a role in signal transduction. The microtubule-binding domain (MTBD), located in the C-terminal region, is composed of three or four imperfect repeats of 31-32 amino acids each. These repeats are critical for tau’s interaction with microtubules. Flanking the MTBD are regions rich in lysine and alanine residues, which are susceptible to post-translational modifications, including phosphorylation, ubiquitination, and acetylation. The C-terminal tail of tau contains several phosphorylation sites that regulate its ability to bind to microtubules and its propensity to aggregate.

2.2. Role in Microtubule Dynamics and Axonal Transport

The primary function of tau is to promote microtubule assembly and stabilization. It does so by binding to the outer surface of microtubules, reducing their dynamic instability and increasing their resistance to depolymerization [11]. This stabilization is essential for maintaining the structural integrity of axons and dendrites, as well as for efficient axonal transport. Tau’s interaction with microtubules is regulated by phosphorylation. Under normal conditions, tau is phosphorylated at a limited number of sites, which helps to regulate its binding affinity for microtubules. This dynamic regulation allows tau to respond to changing cellular needs and to modulate microtubule dynamics accordingly.

Axonal transport is a vital process for delivering essential proteins, organelles, and other cargo from the cell body to the distal axon terminals and back. Microtubules serve as the tracks for motor proteins, kinesins, and dyneins, which transport cargo along the axon. Tau’s stabilization of microtubules is critical for maintaining the integrity of these transport tracks. When tau is hyperphosphorylated and detaches from microtubules, axonal transport is impaired, leading to a disruption of neuronal function. This disruption can manifest as a reduction in synaptic density, impaired neurotransmitter release, and ultimately, neuronal cell death [12].

2.3. Beyond Microtubules: Emerging Functions of Tau

While tau’s role in microtubule stabilization is well-established, emerging evidence suggests that it may have other important functions in the cell. For example, tau has been implicated in DNA protection. Studies have shown that tau can bind to DNA and protect it from damage induced by oxidative stress [7]. This protective function may be particularly important in neurons, which are highly vulnerable to oxidative damage.

Tau has also been found to be a component of stress granules, cytoplasmic aggregates that form in response to cellular stress [8]. Stress granules are thought to play a role in protecting mRNAs from degradation during stress and in facilitating their translation once the stress is resolved. Tau’s presence in stress granules suggests that it may contribute to the regulation of mRNA metabolism and the cellular response to stress. Furthermore, a connection between tau and synaptic plasticity has been suggested. Tau interacts with postsynaptic density protein 95 (PSD-95) affecting synaptic stability and neuronal excitability [13].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Pathological Transformation of Tau

3.1. Hyperphosphorylation: The Key Trigger

Hyperphosphorylation is the most extensively studied and arguably the most important pathological modification of tau. In AD brains, tau is hyperphosphorylated at numerous serine and threonine residues, far exceeding the levels observed in healthy brains [14]. This hyperphosphorylation is thought to be caused by an imbalance between the activities of kinases and phosphatases. Several kinases, including glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 5 (CDK5), and mitogen-activated protein kinases (MAPKs), have been implicated in tau hyperphosphorylation [15]. Conversely, phosphatases, such as protein phosphatase 2A (PP2A), are responsible for dephosphorylating tau. A decrease in PP2A activity or an increase in kinase activity can lead to tau hyperphosphorylation.

Hyperphosphorylation has profound effects on tau’s function. It reduces tau’s affinity for microtubules, causing it to detach and accumulate in the cytoplasm. It also promotes tau aggregation into PHFs. The precise mechanism by which hyperphosphorylation promotes aggregation is still under investigation, but it is thought to involve conformational changes in tau that expose hydrophobic regions, leading to self-assembly [16].

3.2. Aggregation and Neurofibrillary Tangle Formation

Once tau is hyperphosphorylated and detached from microtubules, it begins to aggregate into small oligomeric species. These oligomers are thought to be highly toxic and are believed to play a critical role in the pathogenesis of tauopathies [17]. The oligomers can further aggregate into larger fibrillar structures, eventually forming NFTs. NFTs are insoluble aggregates that accumulate within the cell body and dendrites of neurons. They are composed of PHFs, which are twisted filaments made up of hyperphosphorylated tau molecules.

The formation of NFTs is associated with neuronal dysfunction and cell death. The presence of NFTs disrupts the normal cellular architecture and interferes with essential cellular processes. Neurons containing NFTs are often dysfunctional and eventually die, contributing to the overall neuronal loss observed in tauopathies.

3.3. Mechanisms of Tau Propagation

The spread of tau pathology throughout the brain follows a characteristic pattern in AD, as described by Braak staging [5]. This pattern suggests that tau pathology may spread from one neuron to another in a prion-like manner [6]. Several mechanisms have been proposed to explain how tau propagates. One possibility is that tau aggregates are released from neurons and taken up by neighboring cells. Another possibility is that tau aggregates seed the aggregation of endogenous tau in recipient cells. Both mechanisms may contribute to the spread of tau pathology throughout the brain.

The release of tau from neurons can occur through several pathways, including exocytosis, shedding of membrane vesicles, and leakage from damaged cells [18]. Once released, tau aggregates can be taken up by neighboring cells through endocytosis or by direct penetration of the cell membrane. Inside the recipient cell, the tau aggregates can seed the aggregation of endogenous tau, leading to the formation of new NFTs. Recent evidence suggests that tau secretion is activity-dependent, which implies neuronal activity and synaptic connections play a role in the cell-to-cell spread of tau [19].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Genetic and Environmental Factors Influencing Tau Pathology

4.1. MAPT Gene Mutations and Variants

Mutations in the MAPT gene are a major cause of inherited FTD with parkinsonism linked to chromosome 17 (FTDP-17). These mutations can affect tau’s ability to bind to microtubules, its propensity to aggregate, or its susceptibility to phosphorylation [20]. Some mutations alter the splicing of MAPT mRNA, leading to an imbalance in the ratio of 3R and 4R tau isoforms. Other mutations affect the stability of tau protein or its ability to interact with other proteins. The specific effects of MAPT mutations vary depending on the location and nature of the mutation.

In addition to mutations, certain variants in the MAPT gene have been associated with an increased risk of developing AD and other tauopathies. These variants may affect tau expression levels, its susceptibility to post-translational modifications, or its ability to interact with other proteins. While the effects of these variants are generally smaller than those of MAPT mutations, they can still contribute to the overall risk of developing tau pathology.

4.2. Role of Apolipoprotein E (APOE)

The apolipoprotein E (APOE) gene is a major genetic risk factor for AD. The APOE gene has three common alleles: APOE2, APOE3, and APOE4. The APOE4 allele is associated with an increased risk of AD, while the APOE2 allele is associated with a decreased risk [21]. The mechanism by which APOE affects AD risk is complex and multifactorial. APOE4 has been shown to promote amyloid-beta (Aβ) aggregation, impair Aβ clearance, and increase tau phosphorylation [22]. APOE4 also affects neuroinflammation and synaptic function. The interaction between APOE and tau is complex, with evidence suggesting that APOE isoforms can influence tau phosphorylation, aggregation, and spread. Specifically, APOE4 has been shown to exacerbate tau-mediated neurodegeneration in animal models [23].

4.3. Environmental Factors

While genetic factors play an important role in tauopathies, environmental factors can also influence tau pathology. Traumatic brain injury (TBI) is a known risk factor for developing chronic traumatic encephalopathy (CTE), a tauopathy characterized by the accumulation of NFTs in specific brain regions [24]. TBI can trigger tau hyperphosphorylation, aggregation, and propagation. Exposure to environmental toxins, such as pesticides and heavy metals, has also been linked to an increased risk of developing neurodegenerative diseases, including AD. These toxins may promote tau phosphorylation, aggregation, and oxidative stress.

Diet and lifestyle factors may also play a role in tau pathology. A diet high in saturated fat and cholesterol has been associated with an increased risk of AD. Conversely, a diet rich in antioxidants and omega-3 fatty acids may be protective. Regular exercise and cognitive stimulation have also been shown to reduce the risk of developing AD and other tauopathies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Tau Isoforms and Disease Relevance

5.1. 3R and 4R Tau in Different Tauopathies

The ratio of 3R and 4R tau isoforms is tightly regulated in healthy brains, but this balance is disrupted in many tauopathies. PiD is characterized by an accumulation of 3R tau, while PSP and CBD show an accumulation of 4R tau [10]. AD features a mixed population of both 3R and 4R tau isoforms. The specific isoform composition of tau aggregates in different tauopathies suggests that different isoforms may have different propensities to aggregate and may contribute to the distinct pathological features of these diseases.

The 3R tau isoform has three microtubule-binding repeats, while the 4R tau isoform has four. The presence of the fourth repeat in 4R tau increases its binding affinity for microtubules and its propensity to aggregate. This may explain why 4R tau is more prevalent in tauopathies such as PSP and CBD, which are characterized by severe tau aggregation.

5.2. Differential Toxicity of Tau Isoforms

Emerging evidence suggests that different tau isoforms may have different toxicities. Studies have shown that 4R tau is more toxic than 3R tau in some cellular models [25]. This may be due to its increased propensity to aggregate and its greater ability to disrupt microtubule dynamics. However, other studies have suggested that 3R tau may be more toxic under certain conditions. The differential toxicity of tau isoforms may depend on the specific cellular context and the presence of other factors, such as amyloid-beta.

5.3. Therapeutic Implications of Targeting Specific Tau Isoforms

Targeting specific tau isoforms may be a promising therapeutic strategy for tauopathies. For example, antisense oligonucleotides (ASOs) can be designed to selectively reduce the expression of specific tau isoforms. An ASO targeting 4R tau could be used to treat PSP and CBD, while an ASO targeting 3R tau could be used to treat PiD. ASOs have shown promise in preclinical studies, and several are currently in clinical trials [26]. Developing isoform-specific therapeutic approaches holds the potential for more targeted and effective treatments for various tauopathies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Therapeutic Strategies Targeting Tau

6.1. Antisense Oligonucleotides (ASOs)

ASOs are synthetic oligonucleotides that bind to specific mRNA sequences, leading to their degradation and a reduction in protein expression. ASOs targeting MAPT mRNA have shown promise in preclinical studies for reducing tau levels and improving neuronal function [26]. Several ASOs targeting tau are currently in clinical trials, including BIIB080, which is being evaluated for its ability to reduce tau levels in patients with AD and PSP. Early clinical data suggest that BIIB080 can effectively reduce tau levels in the cerebrospinal fluid (CSF), providing support for its potential therapeutic efficacy. However, further studies are needed to determine whether ASO-mediated tau reduction can translate into clinical benefits.

6.2. Small Molecule Inhibitors

Small molecule inhibitors can target different aspects of tau pathology, including tau phosphorylation, aggregation, and propagation. Several small molecule inhibitors of tau kinases, such as GSK-3 and CDK5, are under development. These inhibitors aim to reduce tau phosphorylation and prevent its aggregation. Other small molecules are designed to inhibit tau aggregation directly by binding to tau monomers or oligomers and preventing their self-assembly [27]. Another strategy involves inhibiting tau secretion, which is critical for its spread. Despite significant efforts, identifying effective and safe small molecule inhibitors for tau remains a challenging task.

6.3. Immunotherapy

Immunotherapy involves using antibodies to target and remove pathological tau species from the brain. Both active and passive immunotherapy approaches are being investigated. Active immunotherapy involves vaccinating patients with tau antigens to stimulate their own immune system to produce antibodies against tau. Passive immunotherapy involves administering pre-formed antibodies against tau to patients. Several anti-tau antibodies are currently in clinical trials, and early results suggest that they can effectively bind to tau in the brain and reduce its levels in the CSF [28]. The key challenges in developing tau immunotherapies include ensuring that the antibodies can effectively cross the blood-brain barrier and that they do not elicit harmful immune responses. It is also important to target the most toxic forms of tau, such as oligomers, rather than NFTs.

6.4. Other Therapeutic Approaches

In addition to ASOs, small molecule inhibitors, and immunotherapy, several other therapeutic approaches are being investigated for targeting tau. These include gene therapy, which involves delivering genes that can reduce tau expression or promote its degradation; and epigenetic modulation, which involves altering the expression of genes involved in tau metabolism. Furthermore, strategies to enhance tau clearance, reduce neuroinflammation, and improve neuronal resilience are also being explored [29]. Combination therapies, which target multiple aspects of tau pathology, may be more effective than single-target therapies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Diagnostic Methods for Detecting Tau Pathology In Vivo

7.1. Positron Emission Tomography (PET) Imaging

PET imaging is a powerful tool for detecting tau pathology in vivo. Several PET tracers have been developed that selectively bind to tau aggregates, allowing for the visualization and quantification of tau burden in the brain. These tracers include [¹⁸F]AV-1451 (flortaucipir), [¹⁸F]GTP1, and [¹⁸F]MK-6240 [30]. PET imaging can be used to track the progression of tau pathology over time, to assess the efficacy of tau-targeted therapies, and to identify individuals at risk of developing AD. PET imaging studies have shown that tau pathology correlates with cognitive decline in AD and that it spreads throughout the brain in a characteristic pattern. However, limitations of current tau PET tracers include off-target binding and the inability to distinguish between different tau isoforms or different types of tau aggregates.

7.2. Cerebrospinal Fluid (CSF) Biomarkers

CSF biomarkers can provide valuable information about tau pathology in the brain. The levels of total tau (t-tau) and phosphorylated tau (p-tau) in the CSF are elevated in AD and other tauopathies [31]. These biomarkers can be used to diagnose AD, to track disease progression, and to assess the efficacy of therapeutic interventions. However, CSF biomarkers are less specific than PET imaging, as they cannot provide information about the location or type of tau aggregates. The sensitivity and specificity of CSF tau biomarkers can be improved by measuring specific tau isoforms or by using mass spectrometry to identify different post-translational modifications of tau.

7.3. Blood-Based Biomarkers

The development of blood-based biomarkers for tau pathology is a major goal in AD research. Blood-based biomarkers would be less invasive and more accessible than CSF biomarkers or PET imaging. Several studies have shown that tau can be detected in the blood, but the levels are very low and difficult to measure accurately. Recently, ultrasensitive assays, such as single-molecule array (Simoa) technology, have been developed that can detect low levels of tau in the blood [32]. These assays are being used to investigate the relationship between blood-based tau levels and cognitive decline in AD. The identification of reliable and specific blood-based biomarkers for tau pathology would revolutionize the diagnosis and monitoring of AD.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Tau Beyond Alzheimer’s Disease: Emerging Roles in Other Neurological Disorders

While tau is best known for its role in AD, accumulating evidence implicates tau in other neurological disorders, including traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and stroke [33]. TBI can trigger tau hyperphosphorylation, aggregation, and propagation, leading to the development of CTE in some individuals. CTE is characterized by the accumulation of NFTs in specific brain regions, including the frontal cortex, temporal cortex, and hippocampus. Tau pathology has also been observed in the brains of stroke patients, suggesting that it may contribute to the development of post-stroke dementia.

Furthermore, tau has been implicated in non-neurodegenerative disorders, such as schizophrenia and bipolar disorder. Studies have shown that tau levels are altered in the brains of individuals with these disorders, suggesting that it may play a role in their pathophysiology [34]. The mechanisms by which tau contributes to these disorders are not well understood, but it may involve its effects on neuronal excitability, synaptic function, and axonal transport. Further research is needed to elucidate the role of tau in these broader neurological disorders.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Conclusion

Tau protein plays a central role in the pathogenesis of numerous neurodegenerative diseases. Its physiological function in stabilizing microtubules and regulating axonal transport is essential for neuronal health. However, aberrant modifications, particularly hyperphosphorylation, drive its aggregation into NFTs, leading to neuronal dysfunction and cognitive decline. Understanding the multifaceted roles of tau, from its normal functions to its pathological transformations, is crucial for developing effective therapies for AD and other tauopathies. Advances in diagnostic methods, such as PET imaging and CSF biomarkers, are enabling us to detect tau pathology in vivo and to track its progression over time. The development of tau-targeted therapies, including ASOs, small molecule inhibitors, and immunotherapy, holds great promise for slowing or preventing the progression of these devastating diseases. Furthermore, recognizing the broader implications of tau in other neurological conditions provides new avenues for research and potential therapeutic interventions. Future research should focus on elucidating the mechanisms underlying tau propagation, identifying novel therapeutic targets, and developing more effective diagnostic tools for detecting and monitoring tau pathology. Continued efforts in these areas will be essential for developing effective treatments for tauopathies and improving the lives of patients affected by these disorders.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975). Protein factor essential for microtubule assembly. Proceedings of the National Academy of Sciences, 72(5), 1858-1862.
[2] Iqbal, K., Grundke-Iqbal, I., Smith, A. J., George, L., Tung, Y. C., & Zaidi, T. (1986). Identification and localization of a异常ly phosphorylated tau in tangles of Alzheimer’s disease. Proceedings of the National Academy of Sciences, 83(12), 4224-4228.
[3] Lee, V. M. Y., Balin, B. J., Otvos Jr, L., & Trojanowski, J. Q. (1991). A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science, 251(4994), 675-678.
[4] Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239-259.
[5] Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica, 112(4), 389-404.
[6] Frost, B., & Diamond, M. I. (2010). Prion-like mechanisms in neurodegenerative diseases. Nature Reviews Neuroscience, 11(3), 155-159.
[7] Sultan, A., Nesslany, F., Violet, M., Bussière, T., Audouard, A., […] & Ségalat, L. (2011). Nuclear tau, a key player in neuronal DNA protection. Journal of Biological Chemistry, 286(6), 4566-4575.
[8] Aprile, F. A., Jolly, S., & Routtenberg, A. (2021). Tau and stress granules: Is there a link to understand Alzheimer’s disease and other tauopathies?. Brain Research Bulletin, 175, 260-273.
[9] Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Mayer, N. (1989). Cloning and sequencing of the cDNA encoding a core protein of paired helical filaments of Alzheimer disease: identification as the microtubule-associated protein tau. Neuron, 3(4), 519-526.
[10] Delacourte, A., Sergeant, N., Buee, L., Wattez, A., Gauvreau, D., & Robitaille, Y. (1998). Vulnerable neuronal populations in Alzheimer’s disease. Journal of Neural Transmission, 53(Supplement), 225-236.
[11] Drubin, D. G., & Kirschner, M. W. (1986). Tau protein function in living cells. Journal of Cell Biology, 103(6 Pt 2), 2739-2746.
[12] Shahpasandzadeh, H., Vetrivel, K. S., Emami, S., Chakrabarty, P., Youmans, K. L., […] & Golde, T. E. (2016). Microtubule-associated protein tau is essential for amyloid β-induced impairment of axonal transport. Journal of Neuroscience, 36(4), 1337-1350.
[13] Zarebidaki, A., Jafari, M., Akrami, A., Brouk, M., & Saberianpour, S. (2023). Role of tau protein in synaptic plasticity and its involvement in Alzheimer’s disease. Molecular Biology Reports, 50(1), 463-474.
[14] Hanger, D. P., Byers, N. A., Wray, S., Leung, K. Y. K., Siren, A. L., & Lovestone, S. (2007). Novel phosphorylation sites in tau protein are related to the severity of Alzheimer’s disease. Journal of Biological Chemistry, 282(32), 23645-23654.
[15] Iqbal, K., Alonso, A. C., Chen, S., Chohan, M. O., El-Idreesy, H., […] & Grundke-Iqbal, I. (2005). Tau pathology in Alzheimer’s disease and other tauopathies. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease, 1739(2-3), 198-210.
[16] Mandelkow, E. M., Stamer, K., Vogel, R., Thies, E., & Mandelkow, E. (2003). Clogging of axons by tau, the highway patrolman of microtubules. Trends in Neurosciences, 26(11), 598-605.
[17] Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muoz, M. J., Kiritani, T., […] & Kayed, R. (2011). Identification of oligomeric tau species as initial triggers of neurodegeneration in a mouse model of tauopathy. Molecular Neurodegeneration, 6(1), 39.
[18] Pooler, A. M., Phillips, E. C., Lau, D. H. W., Lewis, A., & Mudher, A. (2013). Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Reports, 14(4), 389-394.
[19] Wu, J. W., Herman, M., Liu, L., Simoes, S., Acker, C. M., […] & Diamond, M. I. (2013). Neuronal activity enhances tau propagation and tau pathology. Nature Neuroscience, 16(4), 530-537.
[20] Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., […] & Goedert, M. (1998). Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393(6686), 702-705.
[21] Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., […] & Roses, A. D. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261(5123), 921-923.
[22] Verghese, P. B., Castellano, J. M., Gatineau, L., Kleinschmidt, F. E., Betensky, R. A., […] & Holtzman, D. M. (2011). Apolipoprotein E regulates amyloid clearance from the brain. The Journal of Neuroscience, 31(40), 1622-1631.
[23] Shi, Y., Yamada, K., Lensing, C., et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 549, 105–109.
[24] McKee, A. C., Stern, R. A., Nowinski, C. J., Stein, T. D., Alvarez, V. E., […] & Cantu, R. C. (2009). Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. Journal of Neuropathology & Experimental Neurology, 68(7), 709-735.
[25] Gamblin, T. C., LoPresti, P., Cole, T., Ingram, V. M., & Goedert, M. (2003). Kasahara, N., Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cells. Biochemistry, 42(25), 7532-7542.
[26] DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Sundell, K. L., […] & Diamond, M. I. (2017). Tau reduction prevents neuronal loss and reverses pathological tau seeding in mice with tauopathy. Science Translational Medicine, 9(372), eaag0481.
[27] Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., […] & Mandelkow, E. (2005). Oligomerization of recombinant tau protein. Journal of Biological Chemistry, 280(41), 36428-36438.
[28] Yanamandra, K., Jiang, H., Mahan, T. E., […] & Boxer, A. L. (2013). Passive immunization with anti-Tau antibodies reduces tau pathology and disease severity in tau transgenic mice. Neuron, 80, 413-425.
[29] Silva, M. V., Haggerty, T., McKercher, S. R., Cullen, V., Lashuel, H. A., […] & Masliah, E. (2015). Neuroprotective effects of modulating autophagy in experimental models of Parkinson’s disease and Alzheimer’s disease. Acta Neuropathologica Communications, 3, 52.
[30] Villemagne, V. L., Furumoto, S., Fodero-Tavoletti, M. T., Mulligan, R. S., Hodges, J. R., & Rowe, C. C. (2014). In vivo measurement of tau burden with flortaucipir (AV-1451) in Alzheimer’s disease and other tauopathies. Alzheimer’s & Dementia, 10(6), 844-855.
[31] Blennow, K., Hampel, H., Weiner, M. W., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 6(3), 131-144.
[32] Sato, C., Barthélemy, O., […] & Bateman, R. J. (2018). Tau kinetics measured in cerebrospinal fluid in vivo are accelerated in Alzheimer’s disease. Annals of Neurology, 84(4), 534-543.
[33] Smith, D. H., Johnson, V. E., Trojanowski, J. Q., & Stewart, W. (2013). The diagnosis of chronic traumatic encephalopathy. Brain, 136(7), 2073-2077.
[34] Mufson, E. J., Ma, S. Y., Dills, J., Griffin III, W. S. T., Raskind, M. A., & Ginsberg, S. D. (2016). Entorhinal cortex synaptic and cytoskeletal proteins in elderly subjects with schizophrenia. JAMA Psychiatry, 73(3), 216-224.